Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
J Ultrasound Med ; 41(6): 1475-1481, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-34562041

RESUMO

OBJECTIVES: Determine the rate of positive extremity ultrasound exams for DVT in patients with COVID-19 and assess for differences in laboratory values in patients with and without DVT, which could be used as a surrogate to decide the need for further evaluation with ultrasound. METHODS: Retrospective case control study with 1:2 matching of cases (COVID-19+ patients) to controls (COVID-19- patients) based on age, gender, and race. Laboratory values assessed were serum D-dimer, fibrinogen, prothrombin time, international normalized ratio, and C-reactive protein. Demographic variables, comorbidities, and clinical variables including final disposition were also evaluated. P-values for categorical variables were calculated with the chi-square test or Fisher's exact test. P-values for continuous variables were compared with the use of a two-tailed unpaired t-test. RESULTS: The rate of extremity ultrasound exams positive for DVT were similar in patients with (14.7%) and without (19.3%) COVID-19 (P = .423). No significant difference was observed in laboratory values including the D-dimer level in COVID-19 patients without (mean 9523.9 ng/mL (range 339 to >60,000)) or with DVT (mean 13,663.7 ng/mL (range 1193->60,000)) (P = .475). No differences were found in demographic variabilities or co-morbidities among COVID-19 patients with and without extremity DVT. CONCLUSIONS: We found no statistically significant difference in rate of positive DVT studies between COVID-19+ and COVID-19- patients. D-dimer levels are elevated, in some cases markedly, in COVID-19 patients with and without DVTs and therefore these data do not support their use as a surrogate when assessing the need for ultrasound evaluation.


Assuntos
COVID-19 , Trombose Venosa , COVID-19/complicações , Estudos de Casos e Controles , Extremidades/diagnóstico por imagem , Produtos de Degradação da Fibrina e do Fibrinogênio , Humanos , Estudos Retrospectivos , Trombose Venosa/complicações , Trombose Venosa/diagnóstico por imagem
2.
Crit Care Explor ; 2(12): e0288, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33294847

RESUMO

OBJECTIVES: Coronavirus disease 2019 is associated with high mortality rates and multiple organ damage. There is increasing evidence that these patients are at risk for various cardiovascular insults; however, there are currently no guidelines for the diagnosis and management of such cardiovascular complications in patients with coronavirus disease 2019. We share data and recommendations from a multidisciplinary team to highlight our institution's clinical experiences and guidelines for managing cardiovascular complications of coronavirus disease 2019. DESIGN SETTING AND PATIENTS: This was a retrospective cohort study of patients admitted to one of six ICUs dedicated to the care of patients with coronavirus disease 2019 located in three hospitals within one academic medical center in Atlanta, Georgia. MEASUREMENTS/INTERVENTIONS: Chart review was conducted for sociodemographic, laboratory, and clinical data. Rates of specific cardiovascular complications were assessed, and data were analyzed using a chi-square or Wilcoxon rank-sum test for categorical and continuous variables. Additionally, certain cases are presented to demonstrate the sub committee's recommendations. MAIN RESULTS: Two-hundred eighty-eight patients were admitted to the ICU with coronavirus disease 2019. Of these, 86 died (29.9%), 242 (84.03%) had troponin elevation, 70 (24.31%) had dysrhythmias, four (1.39%) had ST-elevation myocardial infarction, eight (2.78%) developed cor pulmonale, and 190 (65.97%) with shock. There was increased mortality risk in patients with greater degrees of troponin elevation (p < 0.001) and with the development of arrhythmias (p < 0.001), cor pulmonale (p < 0.001), and shock (p < 0.001). CONCLUSIONS: While there are guidelines for the diagnosis and management of pulmonary complications of coronavirus disease 2019, there needs to be more information regarding the management of cardiovascular complications as well. These recommendations garnered from the coronavirus disease 2019 cardiology subcommittee from our institution will add to the existing knowledge of these potential cardiovascular insults as well as highlight suggestions for the diagnosis and management of the range of cardiovascular complications of coronavirus disease 2019. Additionally, with the spread of coronavirus disease 2019, our case-based recommendations provide a bedside resource for providers newly caring for patients with coronavirus disease 2019.

3.
ASAIO J ; 62(3): 354-8, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26735556

RESUMO

Extracorporeal membrane oxygenation (ECMO) is an established therapy in the management of patients with refractory cardiogenic shock or acute respiratory failure. In this report, we describe the rapid development and implementation of an organized ECMO program at a facility that previously provided ad hoc support. The program provides care for patients within the Emory Healthcare system and throughout the Southeastern United States. From September 2014 to February 2015, 16 patients were treated with either venovenous or venoarterial ECMO with a survival to decannulation of 53.3% and survival to intensive care unit discharge of 40%. Of the 16 patients, 10 were transfers from outside facilities of which 2 were remotely cannulated and initiated on ECMO support by our ECMO transport team. Complications included intracerebral hemorrhage, bleeding from other sites, and limb ischemia. The results suggest that a rapidly developed ECMO program can provide safe transport services and provide outcomes similar to those in the existing literature. Key components appear to be an institutional commitment, a physician champion, multidisciplinary leadership, and organized training. Further study is required to determine whether outcomes will continue to improve.


Assuntos
Oxigenação por Membrana Extracorpórea , Adulto , Idoso , Oxigenação por Membrana Extracorpórea/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Respiratória/terapia , Choque Cardiogênico/terapia
4.
J Nutr ; 132(10): 3119-22, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12368404

RESUMO

Dietary stearic acid (18:0) lowers plasma and liver cholesterol concentration by reducing intestinal cholesterol absorption. We tested the hypothesis that dietary 18:0 reduces cholesterol absorption by altering hepatic bile acid synthesis and gallbladder bile acid composition. Male Syrian hamsters were fed modified NIH-07 open formula diets, enriched (5 g/100 g diet) in one of the following fatty acids: 18:0, palmitic acid (16:0), trans fatty acids (18:1t), oleic acid (18:1c) or linoleic acid (18:2). After 18 wk, gallbladders were removed and bile acid composition determined by HPLC. The distribution of primary bile acids (mol/100 mol) was unaffected by treatment. In contrast, dietary 18:0 significantly reduced the proportion of hydrophobic secondary bile acids, resulting in a lower hydrophobicity index of the bile. These data suggest that reduced cholesterol absorption by dietary 18:0 is due, at least in part, to reduced cholesterol solubility. The data further suggest that 18:0 may have altered the microflora populations that synthesize secondary bile acids. Although cholesterol 7alpha-hydroxylase (CYP7A1) activity was significantly higher in hamsters fed 18:0 compared with 16:0, this finding is most likely due to increased fecal bile acid output in the 18:0 group rather than transcriptional regulation of CYP7A1 by 18:0 or specific bile acids.


Assuntos
Ácidos e Sais Biliares/análise , Colesterol/metabolismo , Gorduras na Dieta/administração & dosagem , Vesícula Biliar/metabolismo , Absorção Intestinal/fisiologia , Ácidos Esteáricos/administração & dosagem , Animais , Colesterol 7-alfa-Hidroxilase/metabolismo , Cromatografia Líquida de Alta Pressão , Cricetinae , Gorduras na Dieta/farmacologia , Grão Comestível , Fezes/química , Vesícula Biliar/enzimologia , Fígado/enzimologia , Fígado/metabolismo , Masculino , Mesocricetus , Distribuição Aleatória , Solubilidade , Ácidos Esteáricos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...